Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | SARS-CoV-2 | Research

SARS-CoV-2 seroprevalence and associated factors of infection before and after the Delta wave in French Polynesia: a cross-sectional study

Authors: Vincent Mendiboure, Iotefa Teiti, Maite Aubry, Anita Teissier, Tuterarii Paoaafaite, Jessica Vanhomwegen, Jean-Claude Manuguerra, Arnaud Fontanet, Van-Mai Cao-Lormeau, Yoann Madec

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

French Polynesia (FP) comprises 75 inhabited islands scattered across five archipelagos. Between July and October 2021, the SARS-CoV-2 Delta variant triggered a much stronger second epidemic wave in FP than the original Wuhan strain, which was dominant from August 2020 to March 2021. Although previous seroprevalence surveys made it possible to determine the proportion of the population infected by SARS-CoV-2 on the two most populated islands (Tahiti and Moorea) after the first (20.6% in Tahiti and 9.4% in Moorea) and second (57.7% in Tahiti) epidemic waves, no data are available for more remote islands. We used blood samples and personal data collected before, during, and after the second wave from inhabitants of several islands within the five archipelagos to assess the prevalence of SARS-CoV-2 infections and identify associated factors.

Methods

Blood samples and personal data were collected between April and December 2021 as part of the MATAEA study, a cross-sectional survey conducted on a random sample of the adult population representative of the five FP archipelagos and stratified by age and gender. IgG antibodies targeting the SARS-CoV-2 nucleocapsid (N) protein were detected using a recombinant antigen-based microsphere immunoassay. Factors associated with anti-SARS-CoV-2-N seropositivity were identified using logistic regression models.

Results

Of 1,120 participants, 503 (44.9%) tested positive for anti-SARS-CoV-2-N antibodies, corresponding to a weighted prevalence of 56.8% for the FP population aged 18–69 years. The seroprevalence increased from 21.9% to 62.1% before and during/after the Delta wave. Of these infections, only 28.4% had been diagnosed by health professionals. The odds of being seropositive were lower in males, participants recruited before the Delta wave, those who had never been married, those with a diagnosed respiratory allergy, smokers, and those vaccinated against COVID-19.

Conclusions

Our results confirm the high impact of the Delta wave in FP. By the end of 2021, 56.8% of the FP population aged 18–69 years had been infected by SARS-CoV-2; the majority of these infections went undetected. Individuals with respiratory allergies were found to be less susceptible to SARS-CoV-2 infection.
Appendix
Available only for authorised users
Literature
2.
go back to reference PASQUIER J. Bilan démographique 2021. ISPF. 2022. PASQUIER J. Bilan démographique 2021. ISPF. 2022.
4.
go back to reference Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRefPubMedPubMedCentral Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRefPubMedPubMedCentral
5.
go back to reference Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The Lancet. 2020;395(10223):497–506.CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The Lancet. 2020;395(10223):497–506.CrossRef
9.
go back to reference Ministère de la Santé en charge de la Prévention. Bulletin épidémiologique hebdomadaire COVID-19, Polynésie française n°67. 2021;6. Ministère de la Santé en charge de la Prévention. Bulletin épidémiologique hebdomadaire COVID-19, Polynésie française n°67. 2021;6.
10.
go back to reference Ministère de la Santé en charge de la Prévention. Bulletin épidémiologique hebdomadaire COVID-19, Polynésie française n°76. 2021;8. Ministère de la Santé en charge de la Prévention. Bulletin épidémiologique hebdomadaire COVID-19, Polynésie française n°76. 2021;8.
12.
go back to reference Ministère de la Santé en charge de la Prévention. Bulletin épidémiologique hebdomadaire COVID-19, Polynésie française n°69. 2021. Ministère de la Santé en charge de la Prévention. Bulletin épidémiologique hebdomadaire COVID-19, Polynésie française n°69. 2021.
13.
go back to reference Teiti I, Aubry M, Fernandes-Pellerin S, Patin E, Madec Y, Boucheron P, et al. Unravelling the determinants of human health in French Polynesia: the MATAEA project. Front Epidemiol. 2023;27(3):1201038.CrossRef Teiti I, Aubry M, Fernandes-Pellerin S, Patin E, Madec Y, Boucheron P, et al. Unravelling the determinants of human health in French Polynesia: the MATAEA project. Front Epidemiol. 2023;27(3):1201038.CrossRef
14.
go back to reference Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe. 2021;2(2):e60–9.CrossRefPubMedPubMedCentral Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe. 2021;2(2):e60–9.CrossRefPubMedPubMedCentral
15.
go back to reference Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRefPubMed Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRefPubMed
17.
go back to reference Achiron A, Gurevich M, Falb R, Dreyer-Alster S, Sonis P, Mandel M. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. Clin Microbiol Infect. 2021;27(9):1349.e1.CrossRefPubMed Achiron A, Gurevich M, Falb R, Dreyer-Alster S, Sonis P, Mandel M. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. Clin Microbiol Infect. 2021;27(9):1349.e1.CrossRefPubMed
18.
go back to reference Zhan Y, Zhu Y, Wang S, Jia S, Gao Y, Lu Y, et al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. Sig Transduct Target Ther. 2021;6(1):1–12.CrossRef Zhan Y, Zhu Y, Wang S, Jia S, Gao Y, Lu Y, et al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. Sig Transduct Target Ther. 2021;6(1):1–12.CrossRef
19.
go back to reference Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71: 103561.CrossRefPubMedPubMedCentral Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71: 103561.CrossRefPubMedPubMedCentral
20.
go back to reference Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc Natl Acad Sci. 2021;118(34): e2109229118.CrossRefPubMedPubMedCentral Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc Natl Acad Sci. 2021;118(34): e2109229118.CrossRefPubMedPubMedCentral
21.
go back to reference Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PLOS Medicine. 2022;19(5):e1003987. Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PLOS Medicine. 2022;19(5):e1003987.
23.
go back to reference Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1): e044640.CrossRefPubMed Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1): e044640.CrossRefPubMed
24.
go back to reference Meister T, Pisarev H, Kolde R, Kalda R, Suija K, Milani L, et al. Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia. PLoS ONE. 2022;17(6): e0270192.CrossRefPubMedPubMedCentral Meister T, Pisarev H, Kolde R, Kalda R, Suija K, Milani L, et al. Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia. PLoS ONE. 2022;17(6): e0270192.CrossRefPubMedPubMedCentral
25.
go back to reference Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–8.CrossRefPubMedPubMedCentral Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–8.CrossRefPubMedPubMedCentral
26.
go back to reference Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;146(2):327-329.e4.CrossRefPubMedPubMedCentral Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;146(2):327-329.e4.CrossRefPubMedPubMedCentral
27.
go back to reference Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64.CrossRefPubMedPubMedCentral Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64.CrossRefPubMedPubMedCentral
28.
go back to reference Bloom CI, Cullinan P, Wedzicha JA. Asthma Phenotypes and COVID-19 Risk: A population-based observational study. Am J Respir Crit Care Med. 2022;205(1):36–45.CrossRefPubMed Bloom CI, Cullinan P, Wedzicha JA. Asthma Phenotypes and COVID-19 Risk: A population-based observational study. Am J Respir Crit Care Med. 2022;205(1):36–45.CrossRefPubMed
29.
go back to reference Gao Y dong, Ding M, Dong X, Zhang J jin, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–55. Gao Y dong, Ding M, Dong X, Zhang J jin, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–55.
30.
go back to reference Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203-206.e3.CrossRefPubMedPubMedCentral Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203-206.e3.CrossRefPubMedPubMedCentral
31.
go back to reference Ren J, Pang W, Luo Y, Cheng D, Qiu K, Rao Y, et al. Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality. J Allergy Clin Immunol Pract. 2022;10(1):124–33.CrossRefPubMed Ren J, Pang W, Luo Y, Cheng D, Qiu K, Rao Y, et al. Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality. J Allergy Clin Immunol Pract. 2022;10(1):124–33.CrossRefPubMed
32.
go back to reference De Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034–42.CrossRefPubMedPubMedCentral De Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034–42.CrossRefPubMedPubMedCentral
33.
go back to reference Tomaselli V, Ferrara P, Cantone GG, Romeo AC, Rust S, Saitta D, et al. The effect of laboratory-verified smoking on SARS-CoV-2 infection: results from the Troina sero-epidemiological survey. Intern Emerg Med. 2022;17(6):1617–30.CrossRefPubMedPubMedCentral Tomaselli V, Ferrara P, Cantone GG, Romeo AC, Rust S, Saitta D, et al. The effect of laboratory-verified smoking on SARS-CoV-2 infection: results from the Troina sero-epidemiological survey. Intern Emerg Med. 2022;17(6):1617–30.CrossRefPubMedPubMedCentral
34.
go back to reference Weber S, Didelot A, Agrinier N, Peyrin-Biroulet L, Schvoerer E, Rabaud C, et al. SARS-CoV-2 seroprevalence in healthcare workers and risk factors. Infect Dis Health. 2022;27(4):203–10.CrossRefPubMedPubMedCentral Weber S, Didelot A, Agrinier N, Peyrin-Biroulet L, Schvoerer E, Rabaud C, et al. SARS-CoV-2 seroprevalence in healthcare workers and risk factors. Infect Dis Health. 2022;27(4):203–10.CrossRefPubMedPubMedCentral
35.
go back to reference Sidorenkov G, Vonk JM, Grzegorczyk M, Cortés-Ibañez FO, De Bock GH. Factors associated with SARS-COV-2 positive test in Lifelines. Lounis M, editor. PLoS ONE. 2023;18(11):e0294556. Sidorenkov G, Vonk JM, Grzegorczyk M, Cortés-Ibañez FO, De Bock GH. Factors associated with SARS-COV-2 positive test in Lifelines. Lounis M, editor. PLoS ONE. 2023;18(11):e0294556.
36.
go back to reference Benowitz NL, Goniewicz ML, Halpern-Felsher B, Krishnan-Sarin S, Ling PM, O’Connor RJ, et al. Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. Lancet Respir Med. 2022;10(9):900–15.CrossRefPubMedPubMedCentral Benowitz NL, Goniewicz ML, Halpern-Felsher B, Krishnan-Sarin S, Ling PM, O’Connor RJ, et al. Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. Lancet Respir Med. 2022;10(9):900–15.CrossRefPubMedPubMedCentral
37.
go back to reference Kartsonaki C, Baillie JK, Barrio NG, Baruch J, Beane A, Blumberg L, et al. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. Int J Epidemiol. 2023;52(2):355–76.CrossRefPubMedPubMedCentral Kartsonaki C, Baillie JK, Barrio NG, Baruch J, Beane A, Blumberg L, et al. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. Int J Epidemiol. 2023;52(2):355–76.CrossRefPubMedPubMedCentral
38.
go back to reference Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.CrossRefPubMedPubMedCentral Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.CrossRefPubMedPubMedCentral
Metadata
Title
SARS-CoV-2 seroprevalence and associated factors of infection before and after the Delta wave in French Polynesia: a cross-sectional study
Authors
Vincent Mendiboure
Iotefa Teiti
Maite Aubry
Anita Teissier
Tuterarii Paoaafaite
Jessica Vanhomwegen
Jean-Claude Manuguerra
Arnaud Fontanet
Van-Mai Cao-Lormeau
Yoann Madec
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-17869-4

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue